References
- van de KerkhofPCConsistent control of psoriasis by continuous long-term therapy: the promise of biological treatmentsJ Eur Acad Dermatol Venereol200620663965016836489
- HsuSPappKALebwohlMGConsensus guidelines for the management of plaque psoriasisArch Dermatol201214819510222250239
- GottliebABChamianFMasudSTNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaquesJ Immunol200517542721272916081850
- ElliottMBensonJBlankMUstekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseasesAnn N Y Acad Sci200911829711020074279
- NestleFOKaplanDHBarkerJPsoriasisN Engl J Med20093611549650919641206
- NweSMChamplainAHGordonKBRationale and early clinical data on IL-17 blockade in psoriasisExpert Rev Clin Immunol20139767768223899238
- ZabaLCCardinaleIGilleaudeauPAmelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responsesJ Exp Med2007204133183319418039949
- NogralesKEZabaLCGuttman-YasskyETh17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathwaysBr J Dermatol200815951092110218684158
- HarperEGGuoCRizzoHTh17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesisJ Invest Dermatol200912992175218319295614
- KollsJKLindenAInterleukin-17 family members and inflammationImmunity200421446747615485625
- AggarwalSGurneyALIL-17: prototype member of an emerging cytokine familyJ Leukoc Biol20027111811781375
- PappKALangleyRGSigurgeirssonBEfficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging studyBr J Dermatol2013168241242123106107
- RenVDaoHJrPotential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasisClin Cosmet Investig Dermatol201367580
- PappKALeonardiCMenterABrodalumab, an anti-interleukin-17-receptor antibody for psoriasisN Engl J Med2012366131181118922455412
- PappKAReidCFoleyPAnti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trialJ Invest Dermatol2012132102466246922622425
- OsamuNHirotakaNKojiSKenjiTClinical pharmacology of the anti-IL-17 receptor antibody brodalumab (KHK4827) in Japanese normal healthy volunteers and Japanese subjects with moderate to severe psoriasis: a randomized, dose-escalation, placebo-controlled studyJ Dermatol Sci201475320120424957501
- TausendWDowningCTyringSSystematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumabJ Cutan Med Surg201418315616924800703
- SpulsPIHooftLBrodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisalBr J Dermatol2012167471071323013312
- BrownGMalakoutiMWangEKooJYLevinEAnti-IL-17 phase II data for psoriasis: A reviewJ Dermatolog Treat Epup2202014
- GordonKBKimballABChauDImpact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom InventoryBr J Dermatol2014170370571524079852
- ViswanathanHNChauDMilmontCETotal skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasisJ Dermatolog Treat20141524328994
- EndresCJSalingerDHKockKPopulation pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studiesJ Clin Pharmacol201454111230123824846347
- RussellCBRandHBiglerJGene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibodyJ Immunol201419283828383624646743
- Amgen IncAmgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis [news release]Thousand Oaks, CA and LondonAmgen and AstraZeneca;11112014 Available from: http://www.amgen.com/media/media_pr_detail.jsp?releaseID=1988504Accessed February 6, 2015
- SandovalLFPierceAFeldmanSRSystemic therapies for psoriasis: an evidence-based updateAm J Clin Dermatol201415316518024496885